WHAT IS CLAIMED IS:

A pharmaceutical/cosmetic composition of matter, comprising an anti-inflammatory effective amount of at least one peptide containing the lysime-prolinevaline tripeptide sequence, the proline moiety of which existing in its dextrorotatory optical isomer form (DPro), or functional biological equivalent thereof, in a physiologically/pharmaceutically acceptable medium therefor.

10

The pharmaceutical/cosmetic composition as defined in Claim /1, said tripeptide sequence being situated at the Crterminal end of said at least one peptide.

15

20

The pharmaceutical/cosmetic composition as defined in Claim 1, said at least one peptide comprising the lysine-proline-valine tripeptide, the proline moiety of which existing in its dextrorotatory ptical isomer form (DPro).

The pharmaceutical/cosmetic composition as defined in Claim 1, said at least one peptide comprising the lysine-proline-valine tripeptide lysine, proline and valine moieties of which existing in their dextrorotatory optical isomer forms (D-Lys-D-Pro-D-Val).

The pharmaceutical/cosmetic composition 25 as defined in Claim 1, said at least one peptide including at least one protective group therefor.

•		
		18
a.		6. The pharmaceutical/cosmetic composition
		as defined in Claim 5, said at least one protective
Λ	-	as defined in Claim 5, said at least one protective which said Composition Computed and group.
O		
Λ.		7. The pharmacoutical/cosmetic composition tuberain said composition Comprised
15 Ο Λ -	5	as defined in Claim 1, comprising from 10 12M to 10 3M
W		of said tripeptide sequence.
٠.		as defined in Claim 7, comprising from 10 M to 10/4 M of
9.		8. The pharmaceutical/cosmetic composition
J.	•	as defined in Claim 7, comprising from 10-9M to 107 M of
~		asid trimentide sequence.
		9. The pharmaceutical/cosmetic composition wherein said Composition Comprises as defined in Claim 1, comprising from 10 M to 1M of
Q.	10	9. The pharmaceutical/cosmetic composition comprises wherein said composition comprises from 10 to 1M of
a		
		said tripeptide sequence.
		10. The pharmaceutical/cosmetic composition is as defined in Claim 9, comprising from/10 M to 10 M of said tripeptide sequence:
a		10. The pharmaceut teat/composition comprished to the composition of t
a		as defined in Claim 9, Comprising From, 10 17 to 25 to
	15	770 11
		method 11. The pharmacoutical/cosmetic composition comprises i wherein said composition comprises
a		as defined in Claim 1, pomprising a lotion, gel, milk,
		serum, cream, sunscreen, emulsion, shampoo, dentifrice,
		ointment, aerosol or spray.
	20	12. A regime for the treatment of an
		inflammation state afflicting a mammalian organism,
		comprising administering to such organism a
		therapeutically effective amount of the
		pharmaceutical/cosmetic composition as defined by
	25	Claim 1.

•

- 13. The regime as defined by Claim 12, comprising topically administering said pharmaceutical/cosmetic composition to such mammalian organism.
- 14. The regime as defined by Claim 13, comprising topically applying said pharmaceutical/cosmetic composition to the skin, scalp and/or mucous membranes of such mammalian organism.
- 15. The pharmaceutical/cosmetic composition
 10 as defined in Claim 1, further comprising an effective
 anti-inflammatory amount of at least one glucocorticoid,
 vitamin D or derivative thereof, and/or non-steroidal
 anti-inflammatory agent.

and T